# Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

> **NCT05026749** · PHASE3 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 370 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** AZM Group
- **OTHER:** Control Group

## Key facts

- **NCT ID:** NCT05026749
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-27
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-31
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05026749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05026749, "Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05026749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*